Abstract
Optimal treatment for pancreatic adenocarcinoma which is associated with high morbidity and mortality consists of surgery with neoadjuvant or adjuvant chemoradiotherapy. Owing to the high glucose uptake by pancreatic cancer cells, 18F-FDG PET/CT can contribute to staging and therapeutic decision making, preventing futile surgeries in patients with distant metastases. 18F-FDG PET/CT has been shown to offer prognostic information and is a good tool for treatment response assessment particularly in patients with equivocal findings on CT or MRI.
68Gallium-DOTATATE PET/CT is the preferred imaging modality for staging patients with well-differentiated pancreatic neuroendocrine tumors. Therapy with 177Lu-DOTATATE offers survival benefit to patients with metastatic neuroendocrine tumors, unresponsive to other therapeutic measures.